Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 31 · below the Ichimoku cloud · RSI 28 (oversold) · MACD above its signal
None of the 29 investors followed here reported a position in NUWE in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NUWE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 116.7 | -59.9 | -30.5 | 7.6 | -31.9 | -88.7 | -43.0 | -54.6 | -8.9 | -26.4 | −99.1% | ||
| 2025 | 10.8 | 1.6 | -24.8 | 5.3 | -13.1 | -74.4 | 3.9 | -46.9 | -34.3 | -14.6 | -14.7 | -28.7 | −96.3% |
| 2024 | -20.7 | 28.3 | -39.0 | -58.3 | 73.3 | -44.7 | -43.7 | -49.8 | -16.2 | 44.5 | -22.7 | -16.5 | −94.5% |
| 2023 | -17.0 | -12.8 | -37.4 | 0.6 | -45.8 | 1.5 | -6.7 | -27.5 | -21.4 | -45.5 | -15.4 | -12.1 | −94.6% |
| 2022 | 5.3 | -17.5 | 2.0 | -21.8 | -24.1 | -1.7 | -5.1 | 160.7 | -63.0 | -50.0 | -48.1 | -23.4 | −90.6% |
| 2021 | 14.3 | -5.9 | -21.2 | -16.9 | -18.1 | 4.5 | -3.6 | -0.2 | -45.5 | -5.0 | -23.9 | -28.3 | −83.6% |
| 2020 | -44.2 | -2.1 | -6.4 | -6.8 | -7.3 | 26.3 | 77.1 | -56.5 | -21.6 | -30.0 | 13.3 | 1.0 | −73.0% |
| 2019 | 9.8 | 19.5 | -54.3 | -11.9 | -13.0 | -7.6 | -2.1 | -9.8 | -41.6 | -38.7 | -2.2 | -4.4 | −87.5% |
| 2018 | 7.2 | -15.1 | -11.4 | 9.0 | -3.0 | -37.6 | -11.4 | -24.5 | -4.1 | -15.3 | -11.0 | -44.9 | −85.8% |
| 2017 | -49.6 | -15.7 | -59.2 | -58.8 | -22.7 | 77.6 | -33.0 | -1.4 | -13.2 | -40.8 | -41.6 | -15.2 | −98.4% |
| 2016 | -20.0 | -32.4 | 15.1 | -15.5 | 4.2 | -37.8 | 95.7 | -1.1 | -37.1 | -62.5 | 0.0 | 66.7 | −74.1% |
| 2015 | 17.5 | 15.5 | -26.3 | 4.0 | -0.9 | -21.1 | -9.9 | -3.5 | -26.7 | 14.5 | -26.2 | -27.4 | −68.2% |
| 2014 | 2.4 | -16.4 | -29.7 | -0.9 | -6.7 | 3.7 | -11.1 | 12.2 | 0.9 | -14.0 | -6.2 | -6.8 | −56.3% |
| 2013 | -3.9 | 0.0 | 4.4 | -15.2 | 11.8 | -7.3 | 37.2 | 49.4 | 5.2 | -9.0 | -14.0 | 7.2 | +59.4% |
| 2012 | -41.5 | -16.9 | -31.8 | -34.9 | 183.7 | -25.1 | 20.3 | -24.2 | 11.9 | -13.9 | −59.7% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2025 | Erb John LChief Executive Officer | Conversion of Exercise of derivative security at price 0.06 per share. | 1.10M | $66.00K |
No analyst coverage for this instrument.
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.